Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 142 of the 143 references it cites were found in a registry or an index.

Body Fluid Cytokine Levels in Mild Cognitive Impairment and Alzheimer’s Disease: a Comparative Overview

Open access

Abstract

This article gives a comprehensive overview of cytokine and other inflammation associated protein levels in plasma, serum and cerebrospinal fluid (CSF) of patients with Alzheimer's disease (AD) and mild cognitive impairment (MCI). We reviewed 118 research articles published between 1989 and 2013 to compare the reported levels of 66 cytokines and other proteins related to regulation and signaling in inflammation in the blood or CSF obtained from MCI and AD patients. Several cytokines are evidently regulated in (neuro-) inflammatory processes associated with neurodegenerative disorders. Others do not display changes in the blood or CSF during disease progression. However, many reports on cytokine levels in MCI or AD are controversial or inconclusive, particularly those which provide data on frequently investigated cytokines like tumor necrosis factor alpha (TNF-α) or interleukin-6 (IL-6). The levels of several cytokines are possible indicators of neuroinflammation in AD. Some of them might increase steadily during disease progression or temporarily at the time of MCI to AD conversion. Furthermore, elevated body fluid cytokine levels may correlate with an increased risk of conversion from MCI to AD. Yet, research results are conflicting. To overcome interindividual variances and to obtain a more definite description of cytokine regulation and function in neurodegeneration, a high degree of methodical standardization and patients collective characterization, together with longitudinal sampling over years is essential.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s12035-014-8657-1

Cites

142 of 142 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Hypothetical time course of CSF cytokine expression in AD. Graphs display the estimated CSF concentration changes of amyloid and tau protein during the development of AD, as described by others [142]. As different cytokines and other inflammatory proteins appear to display different changes in CSF levels during disease development, they might be divided into groups: First, cytokines like IL-1α or IL-2 which might remain unchanged in AD; Second, cytokines like IL-1β, IL-6 or TNF-α which might increase slowly during disease progression; third, cytokines like IL-18, MCP-1 or IP-10 which might show a peak at certain disease stages, especially at time of MCI to AD conversion. However, data becomes scarce for early disease stages. To test this hypothesis and the grouping of cytokines, longitudinal CSF sampling from individuals at risk of dementia over years would be the most efficient way
Fig. 1 Hypothetical time course of CSF cytokine expression in AD. Graphs display the estimated CSF concentration changes of amyloid and tau protein during the development of AD, as described by others [142]. As different cytokines and other inflammatory proteins appear to display different changes in CSF levels during disease development, they might be divided into groups: First, cytokines like IL-1α or IL-2 which might remain unchanged in AD; Second, cytokines like IL-1β, IL-6 or TNF-α which might increase slowly during disease progression; third, cytokines like IL-18, MCP-1 or IP-10 which might show a peak at certain disease stages, especially at time of MCI to AD conversion. However, data becomes scarce for early disease stages. To test this hypothesis and the grouping of cytokines, longitudinal CSF sampling from individuals at risk of dementia over years would be the most efficient wayCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 143 references

Research works printed but not linked: 1

  1. Doecke JD et al (2012) Blood-based protein biomarkers for diagnosis of Alzheimer disease. Arch Neurol 16:1–8

Cited by

See all 447

Metadata

Authors
Brosseron, F., Krauthausen, M., Kummer, M., & Heneka, M. T.
Affiliations
  • German Center for Neurodegenerative Diseases (DE)
  • University Hospital Bonn (DE)
Corresponding author
Heneka, Michael T.
Venue
Molecular Neurobiology
Published
2014-02-25
Volume
50
Issue
2
Pages
534-544
ISSN
  • 0893-7648 (ISSN-L)
  • 1559-1182
OpenAlex
W2079873627
Cited by
447
References
143
Citations by year
2026: 14 · 2025: 30 · 2024: 40 · 2023: 58 · 2022: 52 · 2021: 49 · 2020: 49 · 2019: 41 · 2018: 33 · 2017: 29 · 2016: 22 · 2015: 23 · 2014: 7
FWCI
13.94
Type
journal article
Language
en
Open access
Locations
  • Molecular Neurobiology (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Open Repository and Bibliography (University of Luxembourg) (submittedVersion, other-oa)
  • DZNE Pub (submittedVersion, cc-by)
Topics
  • Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
Keywords
Alzheimer's disease, mild cognitive impairment, cytokines, neuroinflammation, cerebrospinal fluid biomarkers, plasma biomarkers, TNF-α, interleukin-6, neurodegeneration, inflammation-related proteins
MeSH terms
Alzheimer Disease, Animals, Body Fluids, Humans, Inflammation, Cytokines, Amyloid beta-Peptides, Cognitive Dysfunction

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Body Fluid Cytokine Levels in Mild Cognitive Impairment and Alzheimer’s Disease: a Comparative Overview. https://app.cochat.ai/papers/10.1007/s12035-014-8657-1
The paper
Brosseron, F., Krauthausen, M., Kummer, M., & Heneka, M. T. (2014). Body Fluid Cytokine Levels in Mild Cognitive Impairment and Alzheimer’s Disease: a Comparative Overview. Molecular Neurobiology. https://doi.org/10.1007/s12035-014-8657-1

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.